Levi & Korsinsky, LLP Investigates Breach of Fiduciary Duty by the Board of Pharmacopeia Inc.

Thu. September 25, 2008; Posted: 03:08 PM

NEW YORK, Sep 25, 2008 (GlobeNewswire via COMTEX) -- PCOP | Quote | Chart | News | PowerRating -- Levi & Korsinsky ("L&K") is investigating breaches of fiduciary duty and other violations of state law by the Board of Directors of Pharmacopeia Inc. ("Pharmacopeia" or the "Company") (Nasdaq:PCOP) arising out of their attempt to sell the Company to Ligand Pharmaceuticals Inc. Under the terms of the agreement, Pharmacopeia shareholders would receive 0.58 shares of Ligand Pharmaceuticals stock for each share of Pharmacopeia. Based on the September 24, 2008 closing price of Ligand Pharmaceuticals stock, the value Pharmacopeia shareholders are to receive is approximately $1.81 per share. The transaction also includes a contingent value right under which Pharmacopeia shareholders may receive an additional $15 million under certain circumstances bringing the potential value of the transaction to approximately $70 million. The price is unfair given that the Company's share price traded at $2.87 as recently as August 22, 2008 and the Company has more than $1.49 per share in cash. The proposed acquisition is subject to customary conditions and regulatory approvals.

If you own common stock in Pharmacopeia and wish to obtain additional information, please contact us at the number listed below or visit http://www.zlk.com/pcop.html

Levi & Korsinsky has experience in prosecuting investor securities litigation and an extensive practice in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Levi & Korsinsky, LLP

Levi & Korsinsky, LLP Eduard Korsinsky, Esq. Juan E. Monteverde, Esq. (212) 363-7500 Fax: (212) 363-7171 39 Broadway, Suite 1601 New York, NY 10006 www.zlk.com

For full details on Ligand Pharmaceuticals B (LGND) click here. Ligand Pharmaceuticals B (LGND) has Short Term PowerRatings of 6. Details on Ligand Pharmaceuticals B (LGND) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.